Jojo, Welcome back to the Board. You and all of us who followed BTA know the superiority of Relenza over Tamiflu years before some of the BTA rampers here heard of BTA!
The Relenza superiority only highlights the BTA's pedigree filled board's failures and excesses.
BTA's Seasonal flu sale is close to zilch and likely to remain so. Why? H15N1 resistance to Tamiflu will only increase the sale of the older drugs, some of which no longer have patent protection and have cheap generics on the market. The market is not likely to forget all the bad press on Relenza GSK released during the law suit. The older drugs are cheaper and are easier to administer.
New CEO at GSK better for BTA?? Wow!! We heard this before - the first thing he did was withdrew the earlier $100m law suit offer and the genius Peter Cook settled for $20m. Upon the settlement, he started marketing Relenza Call OPTIONS for which BTA will receive ZILCH royalties until the call options are exercised in a full blown pandemic.
The new CEO has outsmart Peter Cook at every step and corners.
And for those who believe BTA was trading marginally above cash backing - do your research and you will find that the cash backing is NOWHERE near what the brokers' report spruiked.
BTA Price at posting:
41.0¢ Sentiment: Sell Disclosure: Not Held
